Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- PETS +8.9%, STX +8%, ARNC +4.2%, VFC +3.8%, SALT +3.7%, PCH +2.5%,TMUS +1.4%, HAL +1.2%, ITW +1.1%, KMB +0.9%, .
M&A news:
- BSFT +16.9% (confirms deal to be acquired by Cisco (CSCO) for $55/share in cash)
- DEL +7.6% (Potlatch (PCH) and Deltic Timber (DEL) agree to all-stock merger)
Other news:
- AIMT +45.8% (food allergies focused biotech co surging higher following DBVT news (DBVT missed primary endpoint in Phase 3 trial)
- EVOK +23.8% (announces 'positive' topline results from its comparative exposure pharmacokinetic study)
- AGEN +14.3% (launches subsidiary focused on its cell therapy business, named AgenTus Therapeutics)
- PSTI +4.8% (EPO has issued the company a patent titled, 'Methods for Treating Radiation or Chemical Injury' for its PLX-R18 cell therapy)
- DGLY +3.8% (announced the release of the VuLink Pro, which enhances the existing patented technology)
- VKTX +2.7% (announces 'positive' results from a 25-week proof-of-concept study of VK0214)
- ARWR +1.5% (presents data on ARO-AAT; co expects to file a clinical trial application in the first quarter of 2018 to begin first-in-human studies of ARO-AAT)
- TIG +1.3% (receives Orphan Drug Designation from the FDA for Cx601)
- TSLA +1.3% (WSJ discusses that Tesla (TSLA) has agreed to build Shanghai China factory)
- HTHT +1.1% (declares special dividend of $0.16 per ordinary share or $0.64 per ADS)
- CZR +0.8% (Barron's profiles positive view on Caesars), .
Analyst comments:
- SRRA +8.5% (upgraded to Buy from Hold at Jefferies)
- DCPH +3.7% (initiated with a Overweight at JP Morgan)
- ILMN +1.7% (upgraded to Buy from Hold at Deutsche Bank)
- SAIC +1.6% (upgraded to Buy from Neutral at Citigroup)
- CX +1.6% (upgraded to Neutral from Sell at Citigroup)
- CLVS +0.9% (initiated with a Overweight at Barclays)
- DPS +0.6% (upgraded to Outperform from Market Perform at Wells Fargo)
- NVDA +0.5% (target raised to $230 from $180 at Jefferies)